“…The effect of oral pamapimod with pioglitazone on COVID-19 development and recovery in non-hospitalised patients infected with SARS-CoV-2 is currently being investigated in a Phase II clinical trial (KIN-FAST trial, NCT05659459). On the other hand, Thaler et al [ 6 ] show that R-propranolol exhibits broad-spectrum anti-coronavirus activity, inhibiting the replication of MERS-CoV, SARS-CoV and SARS-CoV-2 in several cell lines and in human primary bronchial epithelial cells. Using time-of-addition assays, the authors show that R-propranolol inhibits an unidentified post-entry step of the SARS-CoV-2 replication cycle, likely via a host cell factor.…”